IMMUNITYBIO, INC. Income (Loss) from Equity Method Investments
IMMUNITYBIO, INC. (IBRX) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-02-23
- IMMUNITYBIO, INC. income (loss) from equity method investments for the quarter ending 2024-12-31 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for the quarter ending 2024-09-30 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for the quarter ending 2024-06-30 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for the quarter ending 2024-03-31 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for fiscal 2025 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for fiscal 2024 was $0.00.
- IMMUNITYBIO, INC. income (loss) from equity method investments for fiscal 2023 was -$7.55M.
- IMMUNITYBIO, INC. income (loss) from equity method investments for fiscal 2022 was -$12.11M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | -$1.25M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | -$1.25M derived: sum of 3 quarters · filed 2026-02-23 | -$5.21M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.25M derived: sum of 2 quarters · filed 2026-02-23 | -$5.21M derived: sum of 3 quarters · filed 2026-02-23 | -$7.55M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$1.25M 10-Q · filed 2024-11-12 | -$5.21M derived: sum of 2 quarters · filed 2024-11-12 | -$7.55M 10-Q · filed 2024-11-12 | -$11.10M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$3.96M 10-Q · filed 2024-08-12 | -$6.29M 10-Q · filed 2024-08-12 | -$9.85M derived: sum of 3 quarters · filed 2025-03-03 | -$14.30M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$2.34M 10-Q · filed 2024-05-09 | -$5.89M derived: sum of 2 quarters · filed 2025-03-03 | -$10.35M derived: sum of 3 quarters · filed 2025-03-03 | -$14.25M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$8.01M derived: sum of 2 quarters · filed 2025-03-03 | -$11.91M derived: sum of 3 quarters · filed 2025-03-03 | -$12.11M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$4.46M 10-Q · filed 2023-11-09 | -$8.36M derived: sum of 2 quarters · filed 2023-11-09 | -$8.55M 10-Q · filed 2023-11-09 | -$9.36M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$3.90M 10-Q · filed 2023-08-08 | -$4.10M 10-Q · filed 2023-08-08 | -$4.90M derived: sum of 3 quarters · filed 2024-03-19 | -$4.90M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$197.00K 10-Q · filed 2023-05-11 | -$1.00M derived: sum of 2 quarters · filed 2024-03-19 | -$1.00M derived: sum of 3 quarters · filed 2024-03-19 | -$1.00M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$803.00K derived: sum of 2 quarters · filed 2024-03-19 | -$803.00K derived: sum of 3 quarters · filed 2024-03-19 | -$803.00K 10-K · filed 2024-03-19 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 | |||
| 2015-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.00K derived: sum of 2 quarters · filed 2018-03-12 | $1.00K derived: sum of 3 quarters · filed 2018-03-12 | -$56.00K 10-K · filed 2018-03-12 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 derived: sum of 2 quarters · filed 2016-11-10 | -$57.00K 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$57.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$57.00K 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |